Background: To study the effect of single nucleotide polymorphisms (SNPs) in the thymidylate synthase (TYMS) gene for their value in predicting the efficacy of raltitrexed treatment combined with transcatheter arterial chemoembolization (TACE) for the treatment of primary hepatocellular carcinoma (HCC) cancer. Methods: We conducted a genotypic analysis of the TYMS SNPs rs2790, rs8423, rs502396, rs699517, and rs1004474 in150 HCC patients who were subjected to raltitrexed treatment combined with TACE (study group) and another 150 HCC patients who were treated with doxorubicin combined with TACE (control group). After 1 year of follow-up and interventional therapy, the relationship between the TYMS SNPs and survival rate, and the prognosis for survival were analyzed. Results: After interventional therapy, the response rate (RR) and disease control rate (DCR) of the study group were 52.67% and 87.33%, respectively; whereas the RR and DCR of the control group were 54.67% and 84.67%, respectively. No significant differences were detected by comparison of the RRs (p = 0.728) and DCRs (p = 0.506) between the two groups. The HCC patients' TYMS SNPs rs2790, rs8423, rs502396, rs699517, and rs1004474 were associated with the efficacy and prognosis of the raltitrexed-combined TACE intervention (p < 0.05) yet showed no correlation to the efficacy and prognosis of doxorubicin-combined TACE interventional therapy (p > 0.05). Conclusions: The SNPs of the TYMS genes (rs2790, rs8423, rs502396, rs699517, and rs1004474) are associated with the efficacy and prognosis of raltitrexed treatment in HCC patients.

中文翻译：

---

胸苷酸合酶基因多态性与Raltitrexed联合经导管动脉化疗栓塞治疗肝细胞癌的相关性病例对照研究。

背景：研究胸腺嘧啶合酶（TYMS）基因中的单核苷酸多态性（SNPs）在预测雷替曲塞联合经导管动脉化疗栓塞（TACE）治疗原发性肝细胞癌（HCC）的疗效中的价值。方法：我们对150例接受雷替曲塞联合TACE治疗的HCC患者（研究组）和另外150例接受阿霉素联合TACE治疗的HCC患者进行了TYMS SNPs rs2790，rs8423，rs502396，rs699517和rs1004474的基因型分析。 （控制组）。经过1年的随访和介入治疗，分析了TYMS SNPs与生存率之间的关系以及生存预后。结果：介入治疗后，研究组的缓解率（RR）和疾病控制率（DCR）分别为52.67％和87.33％；对照组的RR和DCR分别为54.67％和84.67％。通过比较两组之间的RR（p = 0.728）和DCR（p = 0.506），没有发现显着差异。肝癌患者的TYMS SNP rs2790，rs8423，rs502396，rs699517和rs1004474与雷特曲塞联合TACE干预的疗效和预后相关（p <0.05），但与阿霉素联合TACE干预的疗效和预后无关治疗（p> 0.05）。结论：TYMS基因（rs2790，rs8423，rs502396，rs699517和rs1004474）的SNP与肝癌患者接受雷替曲塞治疗的疗效和预后相关。分别; 对照组的RR和DCR分别为54.67％和84.67％。通过比较两组之间的RR（p = 0.728）和DCR（p = 0.506），没有发现显着差异。肝癌患者的TYMS SNP rs2790，rs8423，rs502396，rs699517和rs1004474与雷特曲塞联合TACE干预的疗效和预后相关（p <0.05），但与阿霉素联合TACE干预的疗效和预后无关治疗（p> 0.05）。结论：TYMS基因（rs2790，rs8423，rs502396，rs699517和rs1004474）的SNP与肝癌患者接受雷替曲塞治疗的疗效和预后相关。分别; 对照组的RR和DCR分别为54.67％和84.67％。通过比较两组之间的RR（p = 0.728）和DCR（p = 0.506），没有发现显着差异。肝癌患者的TYMS SNP rs2790，rs8423，rs502396，rs699517和rs1004474与雷特曲塞联合TACE干预的疗效和预后相关（p <0.05），但与阿霉素联合TACE干预的疗效和预后无关治疗（p> 0.05）。结论：TYMS基因（rs2790，rs8423，rs502396，rs699517和rs1004474）的SNP与肝癌患者接受雷替曲塞治疗的疗效和预后相关。通过比较两组之间的RR（p = 0.728）和DCR（p = 0.506），没有发现显着差异。肝癌患者的TYMS SNP rs2790，rs8423，rs502396，rs699517和rs1004474与雷特曲塞联合TACE干预的疗效和预后相关（p <0.05），但与阿霉素联合TACE干预的疗效和预后无关治疗（p> 0.05）。结论：TYMS基因（rs2790，rs8423，rs502396，rs699517和rs1004474）的SNP与肝癌患者接受雷替曲塞治疗的疗效和预后相关。通过比较两组之间的RR（p = 0.728）和DCR（p = 0.506），没有发现显着差异。肝癌患者的TYMS SNP rs2790，rs8423，rs502396，rs699517和rs1004474与雷特曲塞联合TACE干预的疗效和预后相关（p <0.05），但与阿霉素联合TACE干预的疗效和预后无关治疗（p> 0.05）。结论：TYMS基因（rs2790，rs8423，rs502396，rs699517和rs1004474）的SNP与HCC患者接受雷替曲塞治疗的疗效和预后相关。rs1004474和rs1004474与雷特曲塞联合TACE干预的疗效和预后相关（p <0.05），但与阿霉素联合TACE介入治疗的疗效和预后无关（p> 0.05）。结论：TYMS基因（rs2790，rs8423，rs502396，rs699517和rs1004474）的SNP与肝癌患者接受雷替曲塞治疗的疗效和预后相关。rs1004474和rs1004474与雷特曲塞联合TACE干预的疗效和预后相关（p <0.05），但与阿霉素联合TACE介入治疗的疗效和预后无关（p> 0.05）。结论：TYMS基因（rs2790，rs8423，rs502396，rs699517和rs1004474）的SNP与肝癌患者接受雷替曲塞治疗的疗效和预后相关。